mikata - RoadRUNNER Motorcycle Touring & Travel Magazine
Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive DCGI approval for this GLP-1 receptor agonist.
Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive DCGI approval for this GLP-1 receptor agonist.
Accelerating access to affordable and innovative medicines Contact Us Get in touch with us regarding any queries. Click here
Dr. Kallam Anji Reddy, a scientist and philanthropist, worked to make medicines more affordable globally. He had a strong interest in drug discovery and played a key role in shaping Indias API industry.
Understanding the Context
Accelerating access to affordable and innovative medicines 2026 Dr. Reddys Laboratories Ltd. All rights reserved.
Manufacturing & Supply Chain Our commitment to operational excellence and rigorous benchmarking drives our ability to deliver high-quality medicines to patients across 83 countries.
Accelerating access to affordable and innovative medicines At Dr. Reddy's work isn't just about titles, it's about skills, growth & opportunities.
Your Trusted Partner for High-Quality, Affordable APIs Dr. Reddys API business is a leading manufacturer and supplier of high-quality quality affordable Active Pharmaceutical Ingredients (APIs) to leading.
Key Insights
Technology Development Centre, Cambridge Dr. Reddys Laboratories (EU) Limited 410 Cambridge Science Park, Milton Road, Cambridge CB4 0PE, United Kingdom
About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984,.
Hyderabad, India, Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as Dr. Reddys), a global.
